IDEA Collider | In conversation with Nooman Haque
Manage episode 337507391 series 3382232
00:20 Introduction: what does Silicon Valley Bank's Life Sciences and Healthcare group do?
01:00 Nooman's background
01:30 How does SVB fit into the innovation ecosystem?
02:00 Lending to companies who don't have products
02:15 How does innovation happen: the myth of the lone inventor; the value of connections
03:15 Parallels to non-pharma innovation models and ecosystems
03:45: Innovation as the deployment into a market for the betterment of people and society
04:10: Invention, innovation and diffusion of the innovation
06:00 How does pharma compare?
06:15 How do the incentives influence R&D?
06:30 'Pharma are largely sales organisations' Large vs small companies
07:30 'Companies are largely "satisfied"'The incentives to do differently are not there...
08:05 Analogs to the movie industry; content is knowledge; integrated model to separating out the value chain
09:50 Where is the Netflix of the pharma world?
10:30 Does the emphasis on launching 'blockbusters' affect the pharma industry?
11:30 Finding the right audience, and the right commercial model, for the right product
12:30 The franchise and the 'repeat successes'
14:00 Innovation in distribution
15:00 'We've got boots on the ground, and therefore we need blockbusters'
17:00 How important will the salesforce be? Will biotechs still need to partner with large pharma?
18:00 Why shouldn't government fund and develop (and distribute) new medicines?
19:20 The analog with US defence procurement, and the role of government funding of invention in the innovation ecosystem
20:20 Anti-microbial resistance - why the failure of the market for solving the problem?
21:00 Agreeing on important problems to solve
23:45 The government as an 'infinite agent'
25:10 Knowing that you're getting innovation within an ecosystem: how to measure?
25:45 A proxy for measuring innovation - the patent
27:00 'Are ideas getting harder to find?' Yes.
27:30 'Compared to 30 years ago, it takes 20 times the effort to deliver Moore's Law' - so there is declining productivity
28:45 Why is it getting harder? It's a diffusion problem
30:00 The silo-isation of pharma: diffusion into organisations
31:00 Comparison to banking - the role of regulation
33:30 Is there anything similar to the role of financial regulation in pharma?
34:20 Could we apply anti-trust in pharma?
36:00 Is our model the right model for the next 150 years?
37:20 Societal innovation - how do new beliefs emerge?
38:30 Sherlock Holmes - the character who's appeared most on screen - not owned by anyone
41:20 Europe vs the USA as a hub of innovation
42:00 'A lot of the inventions in the Industrial Revolution came from outside the UK'
45:00 'If your industry relies on early stage ideas, you need to find ways to get those ideas into the hands of 'ordinary' people'
45:40 Answers looking for questions
47:00 If Google is looking to disrupt itself, why not a pharma company?
47:30 Is it a question of timescales? Is there a necessary pressure in other industries?
49:20 Where does Nooman go to learn about innovation?
50:30 On macro-economists and the absence of bias
51:20 The Grapes of Wrath and innovation
53:30 Deliberative decision making
54:30 How we make choices
56:30 'patent litigation held up the development of the steam engine for two decades'
57:20 The value of the long, historical economics view
58:30 The adjacencies; the first car phone was in the 1950s...
61:20 Innovation in India, China, etc.
63:10 Are you excited for the future?
54 епізодів